Neumora Therapeutics (NMRA) Competitors $10.85 +0.35 (+3.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NMRA vs. HALO, KRYS, ACLX, ADMA, IMVT, SRRK, CRSP, DNLI, TWST, and VCELShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Immunovant (IMVT), Scholar Rock (SRRK), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Twist Bioscience (TWST), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry. Neumora Therapeutics vs. Halozyme Therapeutics Krystal Biotech Arcellx ADMA Biologics Immunovant Scholar Rock CRISPR Therapeutics Denali Therapeutics Twist Bioscience Vericel Neumora Therapeutics (NASDAQ:NMRA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Is NMRA or HALO more profitable? Halozyme Therapeutics has a net margin of 41.43% compared to Neumora Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 179.82% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% Halozyme Therapeutics 41.43%179.82%23.56% Which has more volatility and risk, NMRA or HALO? Neumora Therapeutics has a beta of 3.34, meaning that its share price is 234% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Does the media prefer NMRA or HALO? In the previous week, Halozyme Therapeutics had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 9 mentions for Neumora Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.15 beat Neumora Therapeutics' score of 0.58 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, NMRA or HALO? Halozyme Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.87-5.80Halozyme Therapeutics$947.36M6.31$281.59M$3.0215.55 Does the MarketBeat Community favor NMRA or HALO? Halozyme Therapeutics received 501 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 91.30% of users gave Neumora Therapeutics an outperform vote while only 69.51% of users gave Halozyme Therapeutics an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2191.30% Underperform Votes28.70%Halozyme TherapeuticsOutperform Votes52269.51% Underperform Votes22930.49% Do insiders and institutionals have more ownership in NMRA or HALO? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend NMRA or HALO? Neumora Therapeutics presently has a consensus target price of $23.40, suggesting a potential upside of 115.67%. Halozyme Therapeutics has a consensus target price of $61.11, suggesting a potential upside of 30.13%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryHalozyme Therapeutics beats Neumora Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.75B$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-5.8046.7389.7417.18Price / SalesN/A415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book3.533.894.774.78Net Income-$235.93M-$42.21M$120.15M$225.60M7 Day Performance5.14%-2.15%-1.92%-1.23%1 Month Performance11.45%4.20%11.47%3.36%1 Year Performance-22.44%18.39%30.52%16.60% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.4671 of 5 stars$10.85+3.3%$23.40+115.7%-25.1%$1.75BN/A-5.80108Analyst RevisionGap DownHigh Trading VolumeHALOHalozyme Therapeutics4.9948 of 5 stars$48.47+1.0%$61.11+26.1%+29.1%$6.17B$947.36M15.98390Analyst ForecastPositive NewsKRYSKrystal Biotech4.5187 of 5 stars$172.13+5.2%$206.67+20.1%+45.9%$4.95B$50.70M92.45229Analyst ForecastACLXArcellx3.1329 of 5 stars$85.00+1.4%$105.93+24.6%+49.1%$4.60B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7751 of 5 stars$19.05+2.5%$21.25+11.5%+325.4%$4.50B$382.81M68.32530Positive NewsGap DownIMVTImmunovant1.4556 of 5 stars$27.45+4.5%$47.89+74.5%-28.5%$4.03BN/A-11.84120Analyst ForecastNews CoverageSRRKScholar Rock3.8772 of 5 stars$42.99+2.4%$40.43-6.0%+152.3%$4.02B$33.19M-18.35140Positive NewsCRSPCRISPR Therapeutics2.5528 of 5 stars$44.59+1.9%$77.93+74.8%-33.0%$3.81B$371.21M-15.47473Analyst ForecastDNLIDenali Therapeutics4.4235 of 5 stars$23.68+3.1%$40.40+70.6%+1.3%$3.41B$330.53M-8.49364Positive NewsTWSTTwist Bioscience2.5533 of 5 stars$48.83+2.8%$51.90+6.3%+36.7%$2.90B$312.97M-13.19990VCELVericel1.4381 of 5 stars$57.35-0.2%$59.71+4.1%+66.0%$2.83B$226.84M957.83300Analyst Forecast Related Companies and Tools Related Companies Halozyme Therapeutics Competitors Krystal Biotech Competitors Arcellx Competitors ADMA Biologics Competitors Immunovant Competitors Scholar Rock Competitors CRISPR Therapeutics Competitors Denali Therapeutics Competitors Twist Bioscience Competitors Vericel Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NMRA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts